Slingshot members are tracking this event:

In the second half of 2017, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial on combination of PEG PH20 and atezolizumab in treating gallbladder tumors

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
HALO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, Gallbladder Tumors, Pegph20, Ate Zo Lizumab